Hydroxycamptothecin liposomes based on thermal and magnetic dual-responsive system: preparation,in vitroandin vivoantitumor activity, microdialysis-based tumor pharmacokinetics / Hai-Mei Zhu, Jin-Hui Gu, Yi Xie, Bo Xie, Jia-Jun Ling
Abstract Due to the absence of lactone form of hydroxycamptothecin, the commercially available hydroxycamptothecin injection exhibits inefficient therapeutic effects. In this study, we constructed a novel delivery system (thermosensitive magnetic liposomes) that protects lactone form of hydroxycamptothecin from blood or water. After hydroxycamptothecin was loaded into the thermosensitive magnetic liposome (HCPT/TML), its in vitro and in vivo antitumor activity and microdialysis-based tumour pharmacokinetics were determined. The results demonstrated that HCPT/TMLs possessed favourable physicochemical features and significant cytotoxicity against the Huh-7 cells in vitro . In the in vivo antitumor study and tumour pharmacokinetics, HCPT/TMLs displayed effective targeting delivery and antitumor effects, which corresponded to the determined hydroxycamptothecin concentration in tumour tissue. In conclusion, this thermal and magnetic dual-responsive system can efficiently deliver hydroxycamptothecin to tumour tissue and has great potential application in cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 26(2018), 4, Seite 345-356 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Hai-Mei [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Antitumor activity |
|---|
| Umfang: |
1 Online-Ressource (12 p) |
|---|
| doi: |
10.1080/1061186X.2017.1380654 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011103221 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011103221 | ||
| 003 | DE-627 | ||
| 005 | 20230713210708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2017.1380654 |2 doi | |
| 035 | |a (DE-627)KFL011103221 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/1061186X.2017.1380654 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Zhu, Hai-Mei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxycamptothecin liposomes based on thermal and magnetic dual-responsive system: preparation,in vitroandin vivoantitumor activity, microdialysis-based tumor pharmacokinetics |c Hai-Mei Zhu, Jin-Hui Gu, Yi Xie, Bo Xie, Jia-Jun Ling |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (12 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Due to the absence of lactone form of hydroxycamptothecin, the commercially available hydroxycamptothecin injection exhibits inefficient therapeutic effects. In this study, we constructed a novel delivery system (thermosensitive magnetic liposomes) that protects lactone form of hydroxycamptothecin from blood or water. After hydroxycamptothecin was loaded into the thermosensitive magnetic liposome (HCPT/TML), its in vitro and in vivo antitumor activity and microdialysis-based tumour pharmacokinetics were determined. The results demonstrated that HCPT/TMLs possessed favourable physicochemical features and significant cytotoxicity against the Huh-7 cells in vitro . In the in vivo antitumor study and tumour pharmacokinetics, HCPT/TMLs displayed effective targeting delivery and antitumor effects, which corresponded to the determined hydroxycamptothecin concentration in tumour tissue. In conclusion, this thermal and magnetic dual-responsive system can efficiently deliver hydroxycamptothecin to tumour tissue and has great potential application in cancer treatment | ||
| 653 | |a Hydroxycamptothecin | ||
| 653 | |a liposomes | ||
| 653 | |a thermosensitive release | ||
| 653 | |a targeting delivery | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a microdialysis | ||
| 653 | |a antitumor activity | ||
| 700 | 1 | |a Gu, Jin-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Jia-Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d Abingdon : Taylor & Francis Group, 1993 |g 26(2018), 4, Seite 345-356 |h Online-Ressource |w (DE-627)KFL000006076 |w (DE-600)2041932-6 |w (DE-576)273880632 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2018 |g number:4 |g pages:345-356 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/1061186X.2017.1380654 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_01 | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2018 |e 4 |h 345-356 | ||